医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

2019年02月02日 AM12:17
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics. As part of the Dr. Reddy’s senior leadership team, he will be responsible for the Company’s North America Generics business and will be based in Princeton office, U.S.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190201005324/en/

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories, Inc.  (Phot ...

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories, Inc. (Photo: Business Wire)

“Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage,” explains Kikuchi. “I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the Company’s new growth areas.”

Marc has 20+ years of experience in the Pharmaceutical Industry with extensive knowledge and understanding of Generics. Marc joins Dr. Reddy’s from Zydus Pharmaceuticals, Inc. where he served as CEO, Americas since 2016. Prior to joining Zydus, he held professional leadership roles of increasing responsibility with AmerisourceBergen Corporation, Medrad Inc., PRTM, Johnson & Johnson and Incyte Pharmaceuticals. Marc holds a Bachelor’s Degree in Molecular and Cell Biology with a Biochemistry emphasis from the University of California at Berkeley and Master of Business Administration from Carnegie Mellon University in Strategy, Marketing, and Operations Management.

RDY-0219

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190201005324/en/

CONTACT

INVESTOR RELATIONS
ASHISH GIROTRA
ashishg@drreddys.com
(Ph:+609-375-9805)

MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
(Ph:
+91-40- 49002121)

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • American University of the Caribbean School of Medicine & University of Central Lancashire Launch Unique Medical Program
  • Further Data Analysis of Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate
  • ヒューマネティクス・イノベーティブ・ソリューションズがSATT Conectus Alsaceと提携し、ストラスブール大学が開発したSUFEHMを販売へ
  • ファインデックス、キヤノンメディカルシステムズ株式会社との商品基本取引契約を締結
  • SpeeDxが呼吸器ウイルスのマルチプレックス検査キットを開発